Latest News

This Notice of Modifications includes revisions of the proposed regulations amending the circumstances under which a safe use determination will not be issued and also addresses the limits of the reference to Evidence Code Section 1040 as it relates to "Official Information" for purposes of the Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65).

OEHHA announced a public workshop/comment period on the draft report, "Evaluation of Potential Health Effects of Eating Fish from Selected Water Bodies in the Northern Sierra Nevada Foothills (Nevada, Placer, and Yuba Counties): Guidelines for Sport Fish Consumption."

Effective January 17, 2003 , sodium saccharin is delisted from the list of chemicals as known to cause cancer.   Bromacil lithium salt is listed effective January 17, 2003 as known to the state of California to cause reproductive toxicity.

OEHHA accepted comments on the draft document, Proposal for the Adoption of the Revised Toxicity Equivalency Factor (TEFWHO-97) Scheme, for characterizing adverse health impacts from chlorinated dioxin-like compounds.

OEHHA released for public comment its Proposed Revised Toxicity Equivalency Factors (TEF WHO-97) for PCDDs, PCDFs, and Dioxin-Like PCBs, and held a workshop in support of that effort.

Public comment period on Draft Guidance document for risk assessment at school sites

OEHHA released a draft version of the Air Toxics "Hot Spots" Program Risk Assessment Guidelines Part II: Technical Support Document for Describing Available Cancer Potency Factors. 

OEHHA announces a second public comment period for the revised draft technical support documents for proposed Public Health Goals for 11 chemicals.  These chemicals are: asbestos, barium, beryllium, chlorobenzene, 1,1-dichloroethane, diethylhexyl adipate, ethylene dibromide, hexachlorobenzene, silvex, 1,1,2,2-tetrachloroethane, and toxaphene.

OEHHA announces a second public comment period for the proposed Public Health Goal for Perchlorate.

Background for the December 17, 2002 Carcinogen Identification Committee meeting agenda item: Consideration of request to review statin drugs as a group for subsequent listing.